According to Fortune Business Insights, the global Syphilis Testing Market was valued at USD 24.06 billion in 2025 and is projected to grow from USD 26.86 billion in 2026 to USD 64.82 billion by 2034, registering a CAGR of 0.11% during the forecast period. The market is expanding due to the rising prevalence of sexually transmitted infections, increasing public health screening initiatives, growing awareness regarding early diagnosis, and greater adoption of rapid and automated diagnostic technologies. Healthcare providers are increasingly using molecular diagnostics, immunoassays, point-of-care testing kits, and automated laboratory systems to improve testing efficiency and support early disease detection.

Syphilis Testing Market Growth Drivers

Increasing Prevalence of Sexually Transmitted Infections Globally

The growing incidence of sexually transmitted infections is a major growth driver for the syphilis testing market. More than 7 million new syphilis infections are reported globally each year, increasing demand for rapid and accurate diagnostic solutions. Healthcare providers are integrating syphilis testing into broader infectious disease screening programs, particularly for sexually active adults, pregnant women, and other high-risk populations. Government-supported prenatal testing and community-based healthcare initiatives are also encouraging routine screening. Public health laboratories and hospitals are investing in automated testing systems to manage growing screening volumes efficiently. Increasing adoption of rapid point-of-care tests and molecular diagnostics is further improving accessibility and expanding market penetration.

Syphilis Testing Market Trends

Growing Adoption of Rapid and Multiplex Diagnostic Technologies

Rapid point-of-care testing is becoming an important trend as healthcare providers seek faster diagnosis and treatment decisions. Nearly 59% of healthcare facilities conducting sexually transmitted infection screening prioritize rapid testing technologies. Multiplex diagnostic platforms are also gaining attention because they can detect syphilis alongside HIV and hepatitis within a single testing workflow. Laboratory automation and digitalization are increasing across healthcare facilities, with around 52% of large clinical laboratories integrating automated immunoassay analyzers into infectious disease testing operations. Molecular diagnostics are also gaining importance because of their sensitivity and specificity in early-stage disease detection.

For detailed market insights, visit: https://www.fortunebusinessinsights.com/syphilis-testing-market-117483

Syphilis Testing Market Opportunities

Expansion of Point-of-Care and Home-Based Testing Solutions

The expansion of rapid point-of-care and home-based testing solutions is creating significant opportunities for market participants. Approximately 57% of healthcare organizations are increasing investments in portable testing technologies capable of delivering fast results outside traditional laboratory settings. Community health clinics, mobile healthcare programs, and telemedicine-supported testing environments can benefit from compact diagnostic devices. Home-based sample collection is also gaining popularity because of convenience, privacy, and accessibility. Manufacturers are developing multiplex platforms that combine syphilis, HIV, and hepatitis testing, while digital reporting and AI-assisted diagnostics can improve patient management and laboratory efficiency.

Syphilis Testing Market Segmentation

By Technology: Immunoassay dominated with approximately 57% market share due to its widespread use in hospitals, blood banks, diagnostic laboratories, and public health facilities. Automated immunoassay analyzers support high-volume testing and rapid result generation. Molecular diagnostics accounted for nearly 43%, supported by growing demand for sensitive and specific technologies for early-stage infection detection and confirmatory testing.

By Location of Testing: Laboratory testing dominated with nearly 68% market share, supported by increasing utilization of automated diagnostic systems in hospitals, diagnostic centers, and reference laboratories. Routine sexually transmitted infection screening and prenatal testing programs are major contributors to laboratory testing demand. Public health laboratories accounted for approximately 32%, supported by government-funded infectious disease surveillance and community screening programs.

Syphilis Testing Market Regional Analysis

North America

North America dominated with a 39% market share in 2025. The region benefits from advanced diagnostic infrastructure, laboratory automation, and extensive sexually transmitted infection screening initiatives. The U.S. market is supported by widespread syphilis screening, prenatal testing programs, and advanced diagnostic technologies. Rapid point-of-care diagnostics, molecular testing platforms, automated immunoassays, and digital reporting systems are increasingly being adopted across hospitals, sexual health clinics, and community healthcare centers.

Europe

Europe accounted for 27% of the global market, supported by established healthcare systems, public health awareness, and widespread sexually transmitted infection prevention programs. Germany, the U.K., and France are important markets. Healthcare organizations are investing in laboratory modernization, automated immunoassay analyzers, molecular testing platforms, and multiplex diagnostics. Prenatal screening and high-risk population testing are also supporting regional demand.

Asia-Pacific